- Company
- Impinzi's indication is expected to be approved in Korea
- by Eo, Yun-Ho Nov 10, 2022 05:46am
- Impinzi is also expected to have options for treating immuno-cancer drugs in the area of biliary tract cancer. According to related industries, the Ministry of Food and Drug Safety is reviewing the expansion of biliary tract cancer indications of Imfinzi, an immuno-cancer drug before PD-L1 inhibition mechanism. Permission is possible as early
- Company
- Samjin-Pin to co-develop new targeted protein degrader
- by Lee, Seok-Jun Nov 10, 2022 05:46am
- Samjin Pharm announced on the 9th that it had signed a strategic Memorandum of Understanding (MOU) with the new drug developer Pin Therapeutics to develop a radical and improved treatment for cancer and fibrosis. Under the MOU, Samjin Pharm will conduct a comprehensive study on the targeted protein degrader (TPD) candidate to assess its
- Company
- The number of reimbursed drugs is the lowest in 33 months
- by Chon, Seung-Hyun Nov 9, 2022 05:47am
- The number of medicines listed on the health insurance benefit list is the smallest in about three years. New-entry drugs have decreased significantly due to the price reorganization of generic drugs and joint development regulations. The size of the reimbursed drug has been greatly reduced due to the reorganization of items such as microbial or
- Company
- Atozet market ↑40% in 1 year...Lipitor Plus leads generics
- by Kim, Jin-Gu Nov 9, 2022 05:47am
- The atorvastatin and ezetimibe combination market has grown 40% in a single year. The cumulative prescription amount of related generics increased over twofold and drove the market growth. In particular, Jeil Pharmaceutical and Viatris Korea’s Lipitor Plus is rapidly increasing its influence in the market. Prescription sales of Lipitor Plus
- Company
- SGLT-2 diabetes medication is on the rise
- by Kim, Jin-Gu Nov 8, 2022 05:43am
- The market for diabetes treatments related to SGLT-2 inhibitors has grown by 16% in a year. Analysts say that the use of this drug in the diabetes treatment market is steadily expanding and that major drugs have recently added indications for heart failure treatment, leading to the expansion of appearance. In the first half of next year, Daew
- Company
- 2 new myelofibrosis drugs fail to extend coverage
- by Eo, Yun-Ho Nov 7, 2022 06:06am
- New drugs for the rare disease myelofibrosis are having difficulty expanding coverage in Korea. According to industry sources, after ‘Jakabi (ruxolitinib)’ failed to expand reimbursement in Korea in May, ‘Inrebic (pedratinib),’ the first new drug to be introduced to the field in one decade, also failed to pass the Health Insurance Rev
- Company
- Recobell can be prescribed at infertility centers
- by Eo, Yun-Ho Nov 3, 2022 05:54am
- The infertility treatment Recobell is available in general hospitals. According to related industries, Ferring Pharmaceutical's Recobell passed the Drug Committee of medical institutions with infertility centers such as Sinchon Severance Hospital, Bundang Seoul National University Hospital, and Bundang Cha Hospital. Along with the expansion o
- Company
- Immuno-oncology drugs set out to conquer early stage cancer
- by Nov 3, 2022 05:54am
- The use of immuno-oncology drugs has advanced to the frontline of early-stage cancers. This is because data has demonstrated that the use of immuno-oncology drugs in the early stages increases the possibility of surgery and reduces the possibility of metastasis and recurrence. Following their use in the field of non-small cell lung cancer
- Company
- Hanmi achieves record quarterly performance in 7 years
- by Chon, Seung-Hyun Nov 2, 2022 05:36am
- Hanmi Pharmaceutical recorded the highest performance in 7 years since 2015. Its sales and operating profit were the largest since Q4 2015 when it signed a series of mega technology export deals, thanks to the success of its new combination drug and Beijing Hanmi. On the 1st, Hanmi Pharmaceutical officially announced that its operating profit
- Company
- JW signs new anti-cancer drug R&D contract with KURE AI
- by Nho, Byung Chul Nov 2, 2022 05:35am
- JW Group announced on the 1st that it has signed a joint research contract with U.S. bio venture company KURE AI Therapeutics to develop innovative anti-cancer drugs based on artificial intelligence (AI). Under this contract, JW Pharma and JW CreaGene will launch research and development of three new anticancer drugs using KURE AI's artificia
